Advertisement
JNJ vs PFE
Which Stock Would AI Choose? Johnson & Johnson (JNJ) vs. Pfizer (PFE) Stock Comparison
Key Takeaways
- JNJ has outperformed PFE year-to-date with a return of approximately 10.7% compared to PFE's 8.1%.
- Johnson & Johnson reported strong Q1 2026 sales growth of 9.9%, raising its full-year outlook, while Pfizer faces upcoming earnings with expected EPS declines.
- PFE offers a higher dividend yield of 6.5% versus JNJ's 2.35%, appealing to income-focused investors.
- Both stocks have pulled back in recent weeks, with JNJ down about 6.7% and PFE down around 4% over the past month amid broader market rotations.
- JNJ's market cap exceeds $548 billion, dwarfing PFE's $150 billion, reflecting its diversified portfolio and stability.
- Recent patent settlements bolster PFE's VYNDAMAX revenue protection until 2031, providing a potential catalyst.
Introduction
Johnson & Johnson (JNJ) and Pfizer (PFE) stand as pharmaceutical titans, offering investors exposure to innovative drugs, medical devices, and steady dividends. This stock comparison analyzes their recent market performance, business drivers, and relative positioning in a volatile healthcare sector. Dividend seekers may favor PFE's higher yield, while growth-oriented traders eye JNJ's momentum from strong quarterly results. With both navigating patent challenges and pipeline developments, understanding their contrasts aids decisions on relative performance and market positioning in today's environment.
JNJ Overview and Recent Performance
Johnson & Johnson, a diversified healthcare leader spanning pharmaceuticals, medtech, and innovative medicine, trades around $228 per share with a market cap over $548 billion. In recent market activity, JNJ stock has shown resilience, up over 45% in the past year despite a 6-7% pullback in recent weeks. Q1 2026 results highlighted 9.9% reported sales growth to $24.1 billion, driven by oncology and medtech segments, prompting raised full-year guidance. Key influences include acquisitions like Atraverse Medical for cardiac devices and positive trial data, boosting sentiment amid ongoing talc litigation resolutions. Its P/E ratio (price-to-earnings) of 26.4 and 2.35% dividend yield underscore stability, with analysts lifting targets post-earnings.
PFE Overview and Recent Performance
Pfizer, a global biopharma powerhouse focused on vaccines, oncology, and rare diseases, hovers near $26.50 per share with a $150 billion market cap. Recent weeks saw PFE decline 4% amid anticipation for Q1 earnings, expected to show EPS (earnings per share) drops due to COVID product declines and patent losses. Positive notes include settlements extending VYNDAMAX protection to 2031 and pipeline advances like FDA priority reviews for PADCEV combinations. Year-to-date gains of 8% lag peers, influenced by high short interest and revenue pressures, though its attractive 6.5% dividend yield and lower P/E of 19.5 support income strategies.
Trending AI Robots
Tickeron's Trending AI Robots page showcases the platform's top-performing AI trading bots, curated from hundreds available—specifically 25 standout performers selected from 351 total bots that trade thousands of tickers across diverse strategies. These bots employ varied approaches, from short-term scalping and swing trading to long-term trend following, with performance metrics tailored to current market conditions like volatility in healthcare stocks. While specific win rates, profit factors, and trade counts fluctuate, the trending selection highlights those demonstrating consistent edge in recent simulations and live trading. Investors can explore these bots to automate strategies on tickers like JNJ or PFE, potentially enhancing portfolio efficiency amid shifting sentiment.
Head-to-Head Comparison
JNJ and PFE differ in business models: JNJ's diversification into medtech provides buffers against pharma patent cliffs, unlike PFE's concentrated biopharma exposure vulnerable to COVID revenue drops. Growth drivers favor JNJ, with accelerating sales and oncology momentum versus PFE's stabilizing but challenged pipeline. Recent momentum shows JNJ's post-earnings strength contrasting PFE's pre-earnings caution, though both face 1-month dips. Risk factors include JNJ's litigation overhang and PFE's higher short interest (2.35%), with sector exposure overlapping in immunology but JNJ gaining from devices. Market sentiment leans toward JNJ's stability and raised guidance, while PFE attracts yield hunters despite underperformance.
Tickeron AI Verdict
Tickeron's AI models would likely favor JNJ in the current environment due to its superior trend consistency, operational growth, and positive catalysts like medtech expansions and raised 2026 outlook. PFE's higher yield and patent wins offer appeal, but relative underperformance and earnings risks tilt probabilities toward JNJ for momentum trades. This assessment reflects observable factors like YTD returns and stability, not a buy recommendation.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JNJ is a StrongBuy and PFE is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
JNJ’s FA Score shows that 4 FA rating(s) are green whilePFE’s FA Score has 0 green FA rating(s).
- JNJ’s FA Score: 4 green, 1 red.
- PFE’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
JNJ’s TA Score shows that 6 TA indicator(s) are bullish while PFE’s TA Score has 4 bullish TA indicator(s).
- JNJ’s TA Score: 6 bullish, 4 bearish.
- PFE’s TA Score: 4 bullish, 5 bearish.
Price Growth
JNJ (@Pharmaceuticals: Major) experienced а +7.42% price change this week, while PFE (@Pharmaceuticals: Major) price change was +2.75% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +4.12%. For the same industry, the average monthly price growth was +16.27%, and the average quarterly price growth was +11.13%.
Reported Earning Dates
JNJ is expected to report earnings on Jul 15, 2026.
PFE is expected to report earnings on Aug 04, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+4.12% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| JNJ | PFE | JNJ / PFE | |
| Capitalization | 633B | 139B | 455% |
| EBITDA | 33.7B | 17.2B | 196% |
| Gain YTD | 28.514 | 0.946 | 3,014% |
| P/E Ratio | 26.80 | 19.15 | 140% |
| Revenue | 96.4B | 63.3B | 152% |
| Total Cash | 22.1B | 13.1B | 169% |
| Total Debt | 55B | 63.7B | 86% |
JNJ | PFE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 26 | 58 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 12 Undervalued | 51 Fair valued | |
PROFIT vs RISK RATING 1..100 | 6 | 100 | |
SMR RATING 1..100 | 36 | 77 | |
PRICE GROWTH RATING 1..100 | 12 | 61 | |
P/E GROWTH RATING 1..100 | 17 | 41 | |
SEASONALITY SCORE 1..100 | 75 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
JNJ's Valuation (12) in the Pharmaceuticals Major industry is somewhat better than the same rating for PFE (51). This means that JNJ’s stock grew somewhat faster than PFE’s over the last 12 months.
JNJ's Profit vs Risk Rating (6) in the Pharmaceuticals Major industry is significantly better than the same rating for PFE (100). This means that JNJ’s stock grew significantly faster than PFE’s over the last 12 months.
JNJ's SMR Rating (36) in the Pharmaceuticals Major industry is somewhat better than the same rating for PFE (77). This means that JNJ’s stock grew somewhat faster than PFE’s over the last 12 months.
JNJ's Price Growth Rating (12) in the Pharmaceuticals Major industry is somewhat better than the same rating for PFE (61). This means that JNJ’s stock grew somewhat faster than PFE’s over the last 12 months.
JNJ's P/E Growth Rating (17) in the Pharmaceuticals Major industry is in the same range as PFE (41). This means that JNJ’s stock grew similarly to PFE’s over the last 12 months.
| JNJ | PFE | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 30% | 2 days ago 57% |
| Stochastic ODDS (%) | 2 days ago 42% | 2 days ago 44% |
| Momentum ODDS (%) | 2 days ago 38% | 2 days ago 58% |
| MACD ODDS (%) | 2 days ago 36% | 2 days ago 64% |
| TrendWeek ODDS (%) | 2 days ago 44% | 2 days ago 55% |
| TrendMonth ODDS (%) | 2 days ago 46% | 2 days ago 55% |
| Advances ODDS (%) | 2 days ago 44% | 5 days ago 55% |
| Declines ODDS (%) | 16 days ago 42% | 3 days ago 58% |
| BollingerBands ODDS (%) | 2 days ago 25% | 2 days ago 56% |
| Aroon ODDS (%) | 2 days ago 45% | 2 days ago 59% |
Advertisement
JNJ and
Correlation & Price change
A.I.dvisor indicates that over the last year, JNJ has been loosely correlated with PFE. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if JNJ jumps, then PFE could also see price increases.
PFE and
Correlation & Price change
A.I.dvisor indicates that over the last year, PFE has been loosely correlated with BMY. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if PFE jumps, then BMY could also see price increases.
| Ticker / NAME | Correlation To PFE | 1D Price Change % | ||
|---|---|---|---|---|
| PFE | 100% | +1.84% | ||
| BMY - PFE | 59% Loosely correlated | +4.16% | ||
| MRK - PFE | 55% Loosely correlated | +3.34% | ||
| AMGN - PFE | 53% Loosely correlated | N/A | ||
| BIIB - PFE | 51% Loosely correlated | N/A | ||
| NVS - PFE | 50% Loosely correlated | +3.74% | ||
More | ||||